Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Dermatology and Therapy · 2024-03 · 14 (3) · 729-743
DOI: 10.1007/s13555-024-01122-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology and Therapy, online erschienen am 07.03.2024. Verfasst von Rui Sun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Corporation, Bannockburn, IL, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis.
Abstract (Originalsprache)
INTRODUCTION: Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, we aim to summarize secukinumab safety in clinical trials (CTs) and post-marketing setting (PMS) until 25 June 2022. METHODS: Adverse events (AEs) were summarized with crude reporting rate (RR) per 100 patient-years (PY) in PMS for all reported indications and with exposure-adjusted incident rates (EAIR) per 100 PY in pooled 47 CTs for approved indications. RESULTS: Secukinumab exposure totaled 1,159,260 PY in PMS and 27,765 PY in CTs. AEs were mostly (> 80%) non-serious in PMS. EAIR for serious AEs was 7.0/100 PY. Nasopharyngitis (RR 0.59/100 PY, EAIR 16.08/100 PY) and pneumonia (RR 0.14/100 PY, EAIR 0.17/100 PY) were the most common infection and serious infection, respectively. Candida infections (RR 0.20/100 PY, EAIR 2.16/100 PY) were the most common fungal infections. Inflammatory bowel disease (IBD) was observed in PMS (0.14/100 PY) and CTs (0.26/100 PY). Most (76%) patients with prior IBD did not report IBD flare during CTs. PMS monitoring identified paradoxical skin reactions including dyshidrotic eczema (RR 0.006/100 PY) and pyoderma gangrenosum (RR 0.003/100 PY). CONCLUSION: Secukinumab safety profile with increased patient exposure remained favorable. Paradoxical skin reactions were identified in post-marketing monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Novartis Pharmaceuticals Corporation, Bannockburn, IL, USA.
- Novartis Pharma, Barcelona, Spain.
- Novartis Pharma AG, Basel, Switzerland.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Rheumatology, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, USA.
- University of Washington, Seattle, WA, USA.
Förderung
- Novartis
Zitieren
APA
Sun, R., Bustamante, M., Gurusamy, V. K., Lebwohl, M., Gottlieb, A. B., Mease, P. J., Deodhar, A., Bao, W., Mendelson, M., Porter, B., Chand, D., & Dong, V. (2024). Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials. Dermatology and Therapy, 14(3), 729-743. https://doi.org/10.1007/s13555-024-01122-2
Vancouver
Sun R, Bustamante M, Gurusamy VK, Lebwohl M, Gottlieb AB, Mease PJ, et al. Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials. Dermatology and Therapy. 2024;14(3):729-743. doi:10.1007/s13555-024-01122-2
BibTeX
@article{Sun2024,
author = {Sun, Rui and Bustamante, Mercedes and Gurusamy, Venkatesh Kumar and Lebwohl, Mark and Gottlieb, Alice B and Mease, Philip J and Deodhar, Atul and Bao, Weibin and Mendelson, Meryl and Porter, Brian and Chand, Deepa and Dong, Victor},
title = {Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials},
journal = {Dermatology and Therapy},
year = {2024},
volume = {14},
number = {3},
pages = {729--743},
doi = {10.1007/s13555-024-01122-2}
}
EUVIMED